Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases
ABSTRACTBackground Immunotherapy has shown intracranial efficacy in non-small cell lung cancer (NSCLC) patients with brain metastases. However, predictive biomarkers for intracranial response to immunotherapy are lacking. This post-hoc analysis aimed to explore the potential of immunological cytokin...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2290790 |
| _version_ | 1797401503859736576 |
|---|---|
| author | Meichen Li Jing Chen Hui Yu Baishen Zhang Xue Hou Honghua Jiang Dan Xie Likun Chen |
| author_facet | Meichen Li Jing Chen Hui Yu Baishen Zhang Xue Hou Honghua Jiang Dan Xie Likun Chen |
| author_sort | Meichen Li |
| collection | DOAJ |
| description | ABSTRACTBackground Immunotherapy has shown intracranial efficacy in non-small cell lung cancer (NSCLC) patients with brain metastases. However, predictive biomarkers for intracranial response to immunotherapy are lacking. This post-hoc analysis aimed to explore the potential of immunological cytokines in cerebrospinal fluid (CSF) to predict intracranial tumor response to immunotherapy in patients with brain metastases.Methods Treatment-naive NSCLC patients with brain metastases who received camrelizumab plus chemotherapy were enrolled. Paired plasma and CSF samples were prospectively collected at baseline and the first treatment assessment. All samples were analyzed for 92 immuno-oncology cytokines using Olink’s panels.Results A total of 28 patients were included in this analysis. At baseline, most immunological cytokines were significantly lower in CSF than in plasma, whereas a subset comprising CD83, PTN, TNFRSF21, TWEAK, ICOSLG, DCN, IL-8, and MCP-1, was increased in CSF. Baseline CSF levels of LAMP3 were significantly higher in patients with intracranial tumor response, while the levels of CXCL10, IL-12, CXCL11, IL-18, TIE2, HGF, and PDCD1 were significantly lower. Furthermore, the CXCL10, CXCL11, TIE2, PDCD1, IL-18, HGF, and LAMP3 in CSF were also significantly associated with intracranial progression-free survival for immunotherapy. The identified cytokines in CSF were decreased at the first treatment evaluation in patients with intracranial tumor response. The logistic CSF immuno-cytokine model yielded an AUC of 0.91, as compared to PD-L1 expression (AUC of 0.72).Conclusions Immunological cytokines in CSF could predict intracranial tumor response to immunotherapy in NSCLC patients with brain metastases, and the findings warrant validation in a larger prospective cohort study.Trial registration ClinicalTrials.gov identifier: NCT04211090. |
| first_indexed | 2024-03-09T02:11:05Z |
| format | Article |
| id | doaj.art-b59a437343bd45c7856d98d689ce4eed |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2024-03-09T02:11:05Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-b59a437343bd45c7856d98d689ce4eed2023-12-07T12:35:04ZengTaylor & Francis GroupOncoImmunology2162-402X2024-12-0113110.1080/2162402X.2023.2290790Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastasesMeichen Li0Jing Chen1Hui Yu2Baishen Zhang3Xue Hou4Honghua Jiang5Dan Xie6Likun Chen7Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Oncology, Southern Theater Air Force Hospital, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangzhou, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaABSTRACTBackground Immunotherapy has shown intracranial efficacy in non-small cell lung cancer (NSCLC) patients with brain metastases. However, predictive biomarkers for intracranial response to immunotherapy are lacking. This post-hoc analysis aimed to explore the potential of immunological cytokines in cerebrospinal fluid (CSF) to predict intracranial tumor response to immunotherapy in patients with brain metastases.Methods Treatment-naive NSCLC patients with brain metastases who received camrelizumab plus chemotherapy were enrolled. Paired plasma and CSF samples were prospectively collected at baseline and the first treatment assessment. All samples were analyzed for 92 immuno-oncology cytokines using Olink’s panels.Results A total of 28 patients were included in this analysis. At baseline, most immunological cytokines were significantly lower in CSF than in plasma, whereas a subset comprising CD83, PTN, TNFRSF21, TWEAK, ICOSLG, DCN, IL-8, and MCP-1, was increased in CSF. Baseline CSF levels of LAMP3 were significantly higher in patients with intracranial tumor response, while the levels of CXCL10, IL-12, CXCL11, IL-18, TIE2, HGF, and PDCD1 were significantly lower. Furthermore, the CXCL10, CXCL11, TIE2, PDCD1, IL-18, HGF, and LAMP3 in CSF were also significantly associated with intracranial progression-free survival for immunotherapy. The identified cytokines in CSF were decreased at the first treatment evaluation in patients with intracranial tumor response. The logistic CSF immuno-cytokine model yielded an AUC of 0.91, as compared to PD-L1 expression (AUC of 0.72).Conclusions Immunological cytokines in CSF could predict intracranial tumor response to immunotherapy in NSCLC patients with brain metastases, and the findings warrant validation in a larger prospective cohort study.Trial registration ClinicalTrials.gov identifier: NCT04211090.https://www.tandfonline.com/doi/10.1080/2162402X.2023.2290790Brain metastasescerebrospinal fluidimmunological cytokinesimmunotherapytumor response |
| spellingShingle | Meichen Li Jing Chen Hui Yu Baishen Zhang Xue Hou Honghua Jiang Dan Xie Likun Chen Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases OncoImmunology Brain metastases cerebrospinal fluid immunological cytokines immunotherapy tumor response |
| title | Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases |
| title_full | Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases |
| title_fullStr | Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases |
| title_full_unstemmed | Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases |
| title_short | Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases |
| title_sort | cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non small cell lung cancer patients with brain metastases |
| topic | Brain metastases cerebrospinal fluid immunological cytokines immunotherapy tumor response |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2290790 |
| work_keys_str_mv | AT meichenli cerebrospinalfluidimmunologicalcytokinespredictintracranialtumorresponsetoimmunotherapyinnonsmallcelllungcancerpatientswithbrainmetastases AT jingchen cerebrospinalfluidimmunologicalcytokinespredictintracranialtumorresponsetoimmunotherapyinnonsmallcelllungcancerpatientswithbrainmetastases AT huiyu cerebrospinalfluidimmunologicalcytokinespredictintracranialtumorresponsetoimmunotherapyinnonsmallcelllungcancerpatientswithbrainmetastases AT baishenzhang cerebrospinalfluidimmunologicalcytokinespredictintracranialtumorresponsetoimmunotherapyinnonsmallcelllungcancerpatientswithbrainmetastases AT xuehou cerebrospinalfluidimmunologicalcytokinespredictintracranialtumorresponsetoimmunotherapyinnonsmallcelllungcancerpatientswithbrainmetastases AT honghuajiang cerebrospinalfluidimmunologicalcytokinespredictintracranialtumorresponsetoimmunotherapyinnonsmallcelllungcancerpatientswithbrainmetastases AT danxie cerebrospinalfluidimmunologicalcytokinespredictintracranialtumorresponsetoimmunotherapyinnonsmallcelllungcancerpatientswithbrainmetastases AT likunchen cerebrospinalfluidimmunologicalcytokinespredictintracranialtumorresponsetoimmunotherapyinnonsmallcelllungcancerpatientswithbrainmetastases |